InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 13.70
-0.78 (-5.39%)
Sep 10, 2026, 11:44 AM HKT
InnoCare Pharma Employees
InnoCare Pharma had 1,388 employees as of June 30, 2026. The number of employees increased by 299 or 27.46% compared to the previous year.
Employees
1,388
Change
299
Growth
27.46%
Revenue / Employee
2.31M HKD
Profits / Employee
764.31K HKD
Market Cap
29.73B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,388 | 299 | 27.46% |
| Dec 31, 2023 | 1,089 | 150 | 15.97% |
| Dec 31, 2022 | 939 | 218 | 30.24% |
| Dec 31, 2021 | 721 | 269 | 59.51% |
| Dec 31, 2020 | 452 | 238 | 111.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,768 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
InnoCare Pharma News
- 16 days ago - InnoCare Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 16 days ago - InnoCare Pharma Earnings release: Q2 2026 - Filings
- 16 days ago - InnoCare Pharma Slides: Q2 2026 - Filings
- 6 weeks ago - China's Innocare's psoriasis drug meets main goal in late-stage trial - Reuters
- 1 month ago - InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL - GlobeNewsWire
- 2 months ago - InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China - GlobeNewsWire
- 3 months ago - Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR - GlobeNewsWire
- 3 months ago - ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released - GlobeNewsWire